Questions

FV Frederik A. Verburg
GF Glenn Flux
LG Luca Giovanella
DN Douglas van Nostrand
KM Kristoff Muylle
ML Markus Luster
ask Ask a question
Favorite

For the purpose of the present review, two explicit questions were defined:

Which DTC patients will profit from postoperative RIT in terms of overall and/or cancer-specific survival?

Which DTC patients will profit from postoperative RIT in terms of a longer disease-specific survival/low recurrence rates?

Do you have any questions about this protocol?

Post your question to gather feedback from the community. We will also invite the authors of this article to respond.

post Post a Question
0 Q&A